ClinicalTrials.gg
CompletedNCT06236880Updated Oct 19, 2026

A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

A Phase 2 interventional study of GM-2505 in Major Depressive Disorder, sponsored by AbbVie. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Updated Oct 19, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.

Enrollment
44th of 53
126 · median 442
Started
2024
with 1 other
Phase 2
12 of 53
1 open now
Registered
51st of 53
by date

Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 44th largest by enrollment, is one of 2 that started in 2024, is one of 12 in phase 2, and was the 51st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Depressive Disorder, Major by AbbVie, or all of them as a file.
02

Study summary

This is a three-part Phase 2a study. The aim of Part A is to assess the safety and tolerability and preliminary antidepressant efficacy in patients with MDD who are not currently on an antidepressant therapy. The aim of Part B is to assess the antidepressant efficacy, safety and tolerability in patients with MDD who are partial responders while on a current and adequate single SSRI or SNRI treatment. Part C aims to replicate the monotherapy findings of Part A, but with a lower control group dose.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
  • Adjunctive
  • antidepressant
  • 5HT2a agonist
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patients are male or female, of any ethnic origin.
  2. Patients are aged between 18 to 65 years, inclusive.
  3. Patients meet the , Fifth Edition (DSM-5) diagnostic criteria for recurrent MDD without psychotic features, as assessed with the Mini-International Neuropsychiatric Interview (MINI) at Screening.
  4. Current moderate to severe MDD diagnosis confirmed with a MADRS-SIGMA
  5. Concomitant depression therapy:

    1. (Part A) Patients need to be stable and must not have taken any SSRI or SNRI for at least 6 weeks prior to Screening and must be willing to avoid starting a new pharmacological treatment for MDD until the end of the study procedures and assessments. Discontinuing current treatment is not allowed if done for the purposes of achieving eligibility for this study.
    2. (Part B) Patients need to be on stable treatment with any SSRI or SNRI for at least 6 weeks prior to screening and must be willing to remain on the SSRI or SNRI for the duration of the trial
    3. Patients receiving any form of psychotherapy or counselling must have been receiving therapy at Screening and must be willing to remain in therapy until the end of the study procedures and assessments.

Key Exclusion Criteria:

  1. Patient has current or past primary DSM-5 diagnosis of a psychotic disorder or MDD with psychotic features, bipolar, or related disorders. A current diagnosis of PTSD, complex PTSD and borderline personality disorder are exclusionary. Other psychiatric disorders besides MDD should not be the primary disorder.
  2. In first degree relatives, a history of schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder.
  3. Current or prior (six weeks before Screening) use of any SSRI/SNRI medication (Part A only).
  4. Current or prior (five weeks before Screening) use of any monoamine oxidase inhibitor ([MAO-I]; including phenelzine, tranylcypromine, isocarboxazid, iproniazid, selegiline, rasagiline, the reversible MAO-I moclobemide and the antibiotic linezolid).or any tricyclic antidepressant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Low Dose to High Dose of GM-2505

    Drug: GM-2505

  • Experimental
    Moderate Dose to High Dose of GM-2505

    Drug: GM-2505

  • Active comparator
    Experimental very low dose to very low dose of GM-2505

    Drug: GM-2505

Interventions

  • DrugGM-2505

    IV

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability (Part A, B, and C)

    The primary objective of this study is to evaluate the safety and tolerability of two doses of GM-2505 administered to MDD patients at a 2-week interval between doses.

    Time frame: 99 Days

  2. MADRS Score (Part B and C)

    The estimated difference between Arm 1 and Arm 2 in the changes from baseline in MADRS-SIGMA total score

    Time frame: 29 Days

Secondary outcomes

  1. MADRS-SIGMA total score (Part A)

    Change in MADRS-SIGMA total score between Baseline and Day 29 and comparison of Day 1 low dose vs moderate dose at Day 14

    Time frame: Days 14 and 29

  2. MADRS-SIGMA total score (Part B and C)

    MADRS-SIGMA scores (change from baseline)

    Time frame: All additional timepoints

  3. MADRS-SIGMA total score (Part B and C)

    Response and Remission

    Time frame: Days 14, 29, 43, 71, and 99

  4. PK of GM-2505 (Part C)

    Assess the pharmacokinetics of GM-2505 at very low, moderate, and high doses

    Time frame: Day 16

07

Study locations

1 site
  • MAC Clinical Research
    Manchester, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jul 2026, 29 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 29 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 1, 2024
StartActual
Jan 31, 2024
Primary completionActual
Jul 27, 2026
CompletionActual
Jul 27, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Gilgamesh Pharmaceuticals→AbbVie
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Sponsor Gilgamesh Pharmaceuticals→AbbVie
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06236880
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Jan 31, 2024
Primary completion
Jul 27, 2026
Completion
Jul 27, 2026
Last update
Oct 19, 2026

Study contacts

Gerard Marek, MD
study chair · Gilgamesh Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion